spot_img

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent ...

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected...

Top Stories

admin

Blackbaud Named One of Newsweek’s World’s Greenest Companies 2025

Award Evaluates Global Sustainability Practices, ESG Performance Data  and Key Environmental Metrics SYDNEY, May 20, 2025 /PRNewswire/ -- Blackbaud (NASDAQ: BLKB), the...
admin

Telix at ANZSNM Annual Scientific Meeting 2025

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th...

Most Popular

People

All Eyes on Preslie Ross: A Nationwide Supermodel Calls Florida Home...

admin
People

In-Vitro Toxicology Testing Market is Poised to Attain Valuation of US$...

admin
People

Marie Claire Brings Power Play Event to Atlanta

admin
People

Exosomes Skincare Market to Hit USD 809.5 Mn by 2032, amid...

admin
People

Momcozy Launches CoolFit Nursing Bra Series: Revolutionizing Comfort With High Elasticity...

admin
admin

Thailand Social Commerce Intelligence Report 2025: Market to Grow by 18.6%...

This report provides a detailed data-centric analysis of the social commerce sector in Thailand, covering market opportunities and risks across a range of retail categories. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of social commerce market dynamics, market size and forecast, and...
admin

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2...

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V....
spot_img

Category

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast)...

admin

Elucent Medical Announces Froedtert & the Medical College of Wisconsin Health...

admin